Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, recently entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. plan to conduct research with activators of cardiac myosin in order to identify potential treatments for patients with heart failure. Amgen has obtained an option for the joint development and commercialization of CK-1827452 exercisable during a defined period, the ending of which is dependent on Cytokinetics conduct of further clinical trials of CK-1827452. Cytokinetics cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Ispinesib has been the subject of a broad clinical trials program comprised of nine Phase II clinical trials as well as six Phase I or Ib clinical trials. Cytokinetics plans to conduct additional clinical trials with ispinesib and is conducting a Phase I/II trial of SB-74392
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/7/2015)... 7. Juli 2015 BioClinica®, Inc ... klinische Studien, gab heute bekannt, dass es mit ... bei Gewinnung und Erhalt von Patienten übernommen hat. ... MediciGlobal , Ltd. und Access to Patients, LLC. ... Dienst zum Auffinden von Patienten, die für die ...
(Date:7/7/2015)... 7, 2015   InspireMD, Inc. (NYSE ... in embolic protection systems ("EPS"), today announced that ... integrated with MicroNet ™ has received the ... Product Innovation Award.  Through active market research efforts, ... consultants recognize the successful introduction of new and ...
(Date:7/7/2015)... -- Essentialis, a venture-backed company focused on the development of K ... and metabolic diseases, today announced that Dr. Neil M. ... at the Cantor Fitzgerald Inaugural Healthcare Conference. ... 8, 2015 Time: 8:00 AM Eastern Time Location: ... Essentialis is a Carlsbad ...
Breaking Medicine Technology:BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 5
... NEW YORK, Jan. 13, 2012  The New Year brings hope ... Society (ACS) predicts another 240,000 U.S. men will receive this ... battle we are winning. Prostate cancer -specific deaths dropped ... PSA screening and improved surgical treatment, in the form ...
... 2012 The U.S. Food and Drug Administration today ... by W.L. Gore and Associates Inc. to include treatment ... aortic transection). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... endovascular graft approved by the FDA to treat a ...
Cached Medicine Technology:PSA Testing and Robotic Surgery Take on Prostate Cancer 2PSA Testing and Robotic Surgery Take on Prostate Cancer 3FDA Expands Use of Endovascular Graft to Treat Aortic Tears 2
(Date:7/7/2015)... PHOENIX, (PRWEB) , ... July ... ... Western Refining convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial ... camp mobile program, surpassing their original 2015 fundraising goal by nearly $100,000, ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... rumors about possible facial rejuvenation that have emerged about Hillary Clinton. Two plastic ... of State looks more youthful than she has in some time and speculate ...
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's headquarters to ... is a state of the art building, located with easy access to New York ... said, "We are pleased to service our clients from such a premier location and ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Safe Catch is ... single fish for mercury. Albertsons, Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers Market ... , “We developed the technology to test every fish for mercury,” said Safe Catch ...
(Date:7/7/2015)... ... July 07, 2015 , ... Parents and guardians of ... A Forever Recovery, an open-ended holistic treatment center for drug and alcohol abuse located ... Use and HIV Research has shown a significant increase in the “club drug” use ...
Breaking Medicine News(10 mins):Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2
... team of researchers led by an Indian American scientist ... source of nutrition. // ,Cotton fibre continues to ... are a high source of protein, but the presence ... human consumption. ,To remove gossypol from cottonseeds, ...
... Centre at Canada's University //of British Columbia conducted a ... Alzheimer’s disease. , ,During the study, the researchers ... low-oxygen levels for about 16 hours a day, which ... normal levels of oxygen. ,After a month ...
... report that might alert the antennae of call centre employees, ... nearly two-thirds of call // centers in UK, who are ... to prevent hearing damage in their employees. This revelation is ... centre employees, who are undoubtedly risking an important faculty of ...
... ago this month, German psychiatrist Alois Alzheimer formally ... came to bear his name. While international efforts ... have progressed significantly in recent years, a cure ... research tool developed by Susan Liebman, distinguished university ...
... the obese children, to undergo weight loss surgery. //To implement ... that NHS offers the expensive weight loss surgery, free of ... Excellence (NICE), which is presently embroiled in the Alzheimer’s drugs ... treatment plan, targeting obesity in adults and children. ...
... HIV-infected children in South Kazakhstan has reached 80 with the ... – said the officials and non-governmental groups. It is believed ... which caused the death. ,Chief physician of the ... the press persons on Monday that a child infected with ...
Cached Medicine News:Health News:Yeast Model Shows Promise as Alzheimer's Test 2
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
... (Penicillin G) inhibits bacterial ... synthesis. Streptomycin belongs to ... inhibits bacterial growth by ... is used for prevention ...
... A combination of penicillin and streptomycin ... positive and gram negative bacteria when ... 100,000 I.U. Penicillin/100,000 g/mL Streptomycin per ... in water at concentrations of 5,000 ...
Medicine Products: